A good start of immunotherapy in esophageal cancer
Abstract Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prog...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2336 |
| _version_ | 1797847680994508800 |
|---|---|
| author | Qian Zhao Jinming Yu Xue Meng |
| author_facet | Qian Zhao Jinming Yu Xue Meng |
| author_sort | Qian Zhao |
| collection | DOAJ |
| description | Abstract Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the application of immunotherapy such as immune checkpoint inhibitors, peptide vaccine, adoptive T cell transfer and oncolytic virus in esophageal cancer. Some already have preliminary results and show the advantages of immunotherapy in esophageal cancer, while others are still in progress. This review aims to introduce the feasibility and current status of immunotherapy in esophageal cancer. |
| first_indexed | 2024-04-09T18:15:21Z |
| format | Article |
| id | doaj.art-1ed0a688d4d84cb4b5de1d891a98cf8a |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T18:15:21Z |
| publishDate | 2019-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-1ed0a688d4d84cb4b5de1d891a98cf8a2023-04-13T04:36:19ZengWileyCancer Medicine2045-76342019-08-018104519452610.1002/cam4.2336A good start of immunotherapy in esophageal cancerQian Zhao0Jinming Yu1Xue Meng2Cheeloo College of Medicine ShanDong University Jinan ChinaDepartment of Radiation Oncology Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences Jinan ChinaCheeloo College of Medicine ShanDong University Jinan ChinaAbstract Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the application of immunotherapy such as immune checkpoint inhibitors, peptide vaccine, adoptive T cell transfer and oncolytic virus in esophageal cancer. Some already have preliminary results and show the advantages of immunotherapy in esophageal cancer, while others are still in progress. This review aims to introduce the feasibility and current status of immunotherapy in esophageal cancer.https://doi.org/10.1002/cam4.2336adoptive T‐cell transferbiomarker immune checkpoint inhibitoresophageal cancerimmunotherapyoncolytic viruspeptide vaccine |
| spellingShingle | Qian Zhao Jinming Yu Xue Meng A good start of immunotherapy in esophageal cancer Cancer Medicine adoptive T‐cell transfer biomarker immune checkpoint inhibitor esophageal cancer immunotherapy oncolytic virus peptide vaccine |
| title | A good start of immunotherapy in esophageal cancer |
| title_full | A good start of immunotherapy in esophageal cancer |
| title_fullStr | A good start of immunotherapy in esophageal cancer |
| title_full_unstemmed | A good start of immunotherapy in esophageal cancer |
| title_short | A good start of immunotherapy in esophageal cancer |
| title_sort | good start of immunotherapy in esophageal cancer |
| topic | adoptive T‐cell transfer biomarker immune checkpoint inhibitor esophageal cancer immunotherapy oncolytic virus peptide vaccine |
| url | https://doi.org/10.1002/cam4.2336 |
| work_keys_str_mv | AT qianzhao agoodstartofimmunotherapyinesophagealcancer AT jinmingyu agoodstartofimmunotherapyinesophagealcancer AT xuemeng agoodstartofimmunotherapyinesophagealcancer AT qianzhao goodstartofimmunotherapyinesophagealcancer AT jinmingyu goodstartofimmunotherapyinesophagealcancer AT xuemeng goodstartofimmunotherapyinesophagealcancer |